Zentalis Pharmaceuticals (ZNTL) stock

Cancer medicines , market cap $162M

Medicines for ovarian cancer

Worth $162M

Pre-market

$1.71

-0.58%

Close $1.72 +0.58%

As of 9:05 AM ET pre-market, delayed 15+ min · Live for Pro members

Why ZNTL is down

Down 59% in 3 months while the S&P 500 fell 5%.

Its $174.6M in cash covers about 5 quarters at the past year's pace of $32.0M a quarter.
Arithmetic on filed figures, not a forecast.

Sources: Price history, Nov 6, 2026; Latest balance sheet, Aug 6, 2026

−2Long-term trend below a falling 200-day average, down over two years

Tell me next time ZNTL moves

Free account, no card. An optional alert when ZNTL moves or its score changes.

Or see it live, free until tomorrow morning. No account.

1 more reason, free with an account →1 more reason why ZNTL is down, from its filings, with how the business stands and the timeline, for Pro members.

Quality Score

-6

Poor

In its industry

#232of 281

Biotech

Checks firing

2of 14

Trending down

From 52-week high

-75.3%

under its best in a year

ZNTL's Quality Score rose 2 points on Fri, Nov 6, to -6. Its high and its low were both higher than the day before (2 chart checks started).

Follow ZNTL's trial news. Pro members can get an alert when Zentalis Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ZNTL files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next1H 2027“DENALI Part 2 topline readout expected in 1H 2027 to allow for data maturation post full enrollment”Trial data · SEC filing · Aug 6

Cash$175M, about 5 quarters at the last year's spendingOn Jun 30 · raised money since, not counted · the company says “into late 2027”

Key facts on ZNTL

Key facts on ZNTL
Holding it back	Moves 10.2% a day with no profit behind it
Latest filing	424B5, Aug 14 Raised $80.5M in a sale of shares, about 50% of its market value

1 more reason behind ZNTL's -6, free with an account →4 more reasons behind ZNTL's -6, for Pro members.

ZNTL in the news

ReportExpected to report tomorrow, after the close. Every 3 months, a company tells everyone how much it sold and earned. It fell after 2 of its last 4 reports, -7.7% on average. Past reports ›

What's next

Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$175M, about 5 quarters at the last year's spendingOn Jun 30 · raised money since, not counted · the company says “into late 2027”

ZNTL catalysts

Coming up

After its last 4 reports it closed -7.7% on average, higher 1 of 4 times.

5 past catalysts since 2022, with sizes and sources, for Pro members.

What's next for ZNTL, and how long its cash lasts

Next step the company has named

1H 2027“DENALI Part 2 topline readout expected in 1H 2027 to allow for data maturation post full enrollment”Trial data · SEC filing · Aug 6

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: ASPENOVAPhase 3 · Recruiting · 420 people · main data estimated May 31, 2028 · NCT07546500

2 more trials, 1 with data due this year, 38 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 5 quarters

$175M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into late 2027” (8-K, Aug 6). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Mar 26, 2025)
At-the-market share sales program (S-3, filed Mar 26, 2025)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

PAO and PFO Vincent Vultaggio sold 40,224 shares on Feb 10, under a planned sale. 3 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Julia Eastland buys or sells

For Pro members: every trade, and Julia Eastland’s 12 filings and quotes.

Get an alert when ZNTL files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How ZNTL ranks in Biotech

ZNTL is #232 of 281 by Quality Score.

How ZNTL ranks in Biotech
Rank	Stock	Checks	Quality Score
1	XERSXeris Biopharma	9/14	22
2	ONCBeOne Medicines	6/14	22
3	VCELVericel	8/14	21
	ABCLAbCellera Biologics		Open for its score
	XFORX4 Pharmaceuticals		Open for its score
	ZBIOZenas BioPharma		Open for its score
	ZURAZura Bio		Open for its score
232	ZNTLZentalis Pharmaceuticals	2/14	-6

When does ZNTL report earnings, and what happens after?

Expected to report Tue Nov 10, after the close (tomorrow).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ZNTL reported on Aug 6, 2026

The quarter

The figures are not read from the release yet.

“The increase of $7.6 million was primarily due to a $7.0 million milestone payment to Recurium IP Holdings, LLC required as a result of the commencement of the Phase 3 ASPENOVA clinical trial and an increase of $5.2 million related to clinical expenses and drug manufacturing, including costs associated with advancing the DENALI and ASPENOVA trials.”

The filing on EDGAR

Where the sales came from

ZNTL's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
1H 2027
DENALI Part 2 topline readout	1H 2027

Figures as filed (SEC filing, Aug 6)

The numbers

Market value: $162M; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ZNTL: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-21.4%0.0%-15.6%

Mar 26May 12Aug 6

Reported	When	Gap	Reaction	5 days
Aug 6, 2026After close	After close	-6.4%	-15.6%	-17.0%
May 12, 2026After close	After close	-3.0%	0.0%	-17.3%
Mar 26, 2026After close	After close	-2.6%	-21.4%	-1.5%

ZNTL closed higher after 1 of its last 4 reports.

All 4 reports, and ZNTL's Quality Score going into each

Everyone reporting earnings this week

ZNTL sales and profit by year

Profit by year

Sales grew in one of the last three years, to $0 in 2025. It lost money in each of the four years.

ZNTL has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on ZNTL, and all 14 on every stock.Get in free →

ZNTL RSI on Nov 6: 26.4, below its 50-day and 200-day averages

Not scored

RSI 26.4, MACD below signal, below both averages. Not scored.13 readings

The deep dive on ZNTL

What it does and how it makes money1 findingFor Pro members1 finding on what ZNTL does and how it makes money, for Pro members
What changed in its filings1 findingA new heading in its "Risk Factors" this year: "Current and future healthcare reform legislation or regulation may increase the difficulty and cost for us to commercialize any approved product candidate and may adversely affect the prices we may obtain and may have a negative impact on our business and …" (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Mar 26, 2026, against the one of Mar 26, 2025
Who holds and trades it2 findings10% owner Walters Group bought $15.2M of shares on the open market on Aug 14, 2026, the only insider trade in 90 days.Form 4, filed Aug 19, 2026

ZNTL share count over time

1% fewer shares than a year earlier.

Weighted shares, quarter to Jun 30, 2026, both from one filing

Shares of ZNTL outstanding, as filed
Shares outstanding	As of
71.7M	Aug 3, 2026
71.2M	May 8, 2026
70.9M	Mar 20, 2026
72.3M	Nov 1, 2025

Offerings, shelves, and splits of ZNTL, from its filings
From its filings	Filed
Raised $80.5M in a sale of shares, about 50% of its market value	Aug 14, 2026
Registered shares for a later sale (S-3)	Mar 26, 2025
Registered shares for a later sale (S-3ASR)	Feb 29, 2024

ZNTL insider trades

One insider bought $15.2M across 1 filing in the last 6 months. No open-⁠market sales on record. The newest:

BuyWalters Group$15.2M10% ownerat $3.50 on Aug 14, filed Aug 19

BuyWalters Group10% owner$15.2Mat $3.50 on Aug 14, filed Aug 19

ZNTL's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Julia Marie EastlandCEO & President · 2 trades
Vincent VultaggioPAO and PFO · 5 trades
Ingmar BrunsChief Medical Officer · 2 trades
David Michael JohnsonDirector · no trades on file
Enoch KariukiDirector · no trades on file
Jan SkvarkaDirector · no trades on file
Luke Nathaniel WalkerDirector · no trades on file
Scott Dunseth MyersDirector · no trades on file

One more officer or director files at ZNTL.

See insider trades by person

Which ETFs hold ZNTL?

In ETFs: ZNTL is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

106 employeesSan Diego, CAzentalis.com

What Zentalis Pharmaceuticals says it competes with

“The biotechnology and pharmaceutical industries are characterized by rapid technological advancement, significant competition and an emphasis on intellectual property.”

From its annual report, SEC filing · Mar 26, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on ZNTL and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn ZNTL's score around: 8 things
4 more filings explained, a plain line each
5 more things pulling ZNTL's score down

BreakawayAug 19Walters Group bought ZNTL$15.2M at $3.50, filed Aug 19

Alerts are optional.

See ZNTL's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: ZNTL's Quality Score is -6 (Poor), #232 of 281 in Biotech. Insiders bought $15.2M in the last 6 months (Form 4).

What does ZNTL's Quality Score say?

ZNTL scores -6 today, which Breakaway calls Poor. It is #232 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 59% in 3 months while the S&P 500 fell 5%. Cash lasts about 5 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ZNTL's Quality Score?

ZNTL scores -6 today, which Breakaway calls Poor (below zero). That is #232 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ZNTL's -6.

Are insiders buying ZNTL?

One insider bought $15.2M across 1 filing in the last 6 months. No open-⁠market sales on record. The newest is Walters Group, 10% owner, who bought $15.2M on Aug 14.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.